Shattuck Labs, Inc. Payments of Stock Issuance Costs
Shattuck Labs, Inc. (STTK) reported Payments of Stock Issuance Costs of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-01.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2026-03-05
- Shattuck Labs, Inc. payments of stock issuance costs for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. payments of stock issuance costs for the quarter ending 2024-12-31 was $0.00.
- Shattuck Labs, Inc. payments of stock issuance costs for the quarter ending 2024-03-31 was $356.00K.
- Shattuck Labs, Inc. payments of stock issuance costs for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. payments of stock issuance costs for fiscal 2024 was $17.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $17.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | $17.00K 10-Q · filed 2025-11-06 | |||
| 2024-03-31 | $356.00K 10-Q · filed 2025-05-01 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 | |||
| 2020-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.25M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $111.00K 10-Q · filed 2021-08-12 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |